PRESS RELEASE published on 05/18/2026 at 17:19, 3 months 29 days ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Valneva SE (ISIN: FR0004056851) research, maintains Buy recommendation with lowered price target. Q1/26 sales declined by 37.2% to €30.9m. Market awaiting Pfizer's BLA submission for Lyme disease vaccine candidate LB6V Buy Recommendation Research Update Valneva SE Q1/26 Sales Pfizer BLA Submission
BRIEF published on 05/06/2026 at 11:41, 4 months 11 days ago Valneva announces the publication of its financial results for the first quarter of 2026 Financial Results Web Conference Clinical Development Valneva Vaccines
PRESS RELEASE published on 05/06/2026 at 11:36, 4 months 11 days ago Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026 Valneva SE to report First Quarter 2026 Consolidated Financial Results on May 13, 2026. Live webcast available for discussion and business update Financial Results Business Update Valneva SE Live Webcast Vaccine Company
BRIEF published on 03/31/2026 at 14:30, 5 months 16 days ago Valneva's Lyme Disease Vaccine Shows Promise Despite Missed Trial Endpoint FDA Approval Price Target Phase 3 Trial Valneva SE Lyme Disease Vaccine
PRESS RELEASE published on 03/31/2026 at 14:25, 5 months 16 days ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Valneva SE (FR0004056851) analysis post Lyme phase 3 trial topline results with Pfizer. Despite missing primary endpoint, optimism remains for FDA approval FDA Approval First Berlin Equity Research Valneva SE Pfizer Lyme Vaccine
BRIEF published on 03/26/2026 at 17:50, 5 months 21 days ago Valneva at the 25th World Vaccine Congress in Washington Valneva World Vaccine Congress Clinical Studies Vaccination Chikungunya
BRIEF published on 03/23/2026 at 12:22, 5 months 24 days ago Pfizer and Valneva unveil promising results for their Lyme disease vaccine Valneva Vaccine Phase 3 Pfizer Lyme
BRIEF published on 02/20/2026 at 12:01, 6 months 25 days ago Valneva SE: Research Update and Financial Projections Valneva SE Financial Update Lyme Vaccine Third-Party Sales Target Price Adjustments
PRESS RELEASE published on 02/20/2026 at 11:56, 6 months 25 days ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research GmbH updated Valneva SE's classification to Buy with a target price of €6.60. Details on 2025 revenues, cash figures, and 2026 guidance included Buy Recommendation Valneva SE First Berlin Equity Research GmbH 2025 Revenues 2026 Guidance
BRIEF published on 01/09/2026 at 07:05, 8 months 8 days ago Valneva Engages Investors at J.P. Morgan Healthcare Conference Valneva Investor Meetings Lyme Disease Vaccine J.P. Morgan Conference Vaccine Portfolio
Published on 09/17/2026 at 12:00, 8 minutes ago Banyan Gold Intersects 1.05 g/t Gold over 52.8 metres and Bonanza-Grade Gold at Powerline Deposit, AurMac, Yukon, Canada
Published on 09/17/2026 at 10:00, 2 hours 8 minutes ago Eagle Plains Reports Additional Results from Drilling at the Don Lake Uranium Project, Saskatchewan
Published on 09/16/2026 at 23:45, 12 hours 23 minutes ago Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 14 hours 38 minutes ago Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 19 hours 13 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/17/2026 at 11:30, 38 minutes ago EyeROV: Indian Deep-Tech Startup Showcases its Underwater Drones to World Leaders
Published on 09/17/2026 at 11:00, 1 hour 8 minutes ago ABB Ltd: ABB share buybacks - September 10, 2026 - September 16, 2026
Published on 09/17/2026 at 10:41, 1 hour 27 minutes ago elumeo SE successfully completes a cash capital increase
Published on 09/17/2026 at 10:40, 1 hour 28 minutes ago Making the Most of Every Ray, Powering the Unpowered: 2026 Global Low-Carbon Industry Forum Explores Pathways to Bridge the Electricity Gap
Published on 09/16/2026 at 17:45, 18 hours 23 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 5 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 18 hours ago Report on the Combined General Meeting of the 10th of September 2026
